|
||||||
|
 | Fusion Gene Summary |
| Fusion Gene ORF analysis |
| Fusion Genomic Features |
| Fusion Protein Features |
| Fusion Gene Sequence |
| Fusion Gene PPI analysis |
| Related Drugs |
| Related Diseases |
Fusion gene:BARD1-C6orf222 (FusionGDB2 ID:HG580TG389384) |
Fusion Gene Summary for BARD1-C6orf222 |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: BARD1-C6orf222 | Fusion gene ID: hg580tg389384 | Hgene | Tgene | Gene symbol | BARD1 | C6orf222 | Gene ID | 580 | 389384 |
| Gene name | BRCA1 associated RING domain 1 | BCL2 interacting protein 5 | |
| Synonyms | - | C6orf222 | |
| Cytomap | ('BARD1')('C6orf222') 2q35 | 6p21.31 | |
| Type of gene | protein-coding | protein-coding | |
| Description | BRCA1-associated RING domain protein 1BRCA1-associated RING domain gene 1RING-type E3 ubiquitin transferase BARD1 | protein BNIP5uncharacterized protein C6orf222 | |
| Modification date | 20200322 | 20200313 | |
| UniProtAcc | Q99728 | . | |
| Ensembl transtripts involved in fusion gene | ENST00000260947, ENST00000449967, ENST00000432456, ENST00000471787, | ||
| Fusion gene scores | * DoF score | 3 X 4 X 3=36 | 1 X 1 X 1=1 |
| # samples | 4 | 2 | |
| ** MAII score | log2(4/36*10)=0.15200309344505 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0 | log2(2/1*10)=4.32192809488736 | |
| Context | PubMed: BARD1 [Title/Abstract] AND C6orf222 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Most frequent breakpoint | BARD1(215645283)-C6orf222(36291967), # samples:1 BARD1(215645284)-C6orf222(36291967), # samples:1 | ||
| Anticipated loss of major functional domain due to fusion event. | BARD1-C6orf222 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. BARD1-C6orf222 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. BARD1-C6orf222 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. BARD1-C6orf222 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. BARD1-C6orf222 seems lost the major protein functional domain in Hgene partner, which is a CGC due to the frame-shifted ORF. BARD1-C6orf222 seems lost the major protein functional domain in Hgene partner, which is a epigenetic factor due to the frame-shifted ORF. BARD1-C6orf222 seems lost the major protein functional domain in Hgene partner, which is a tumor suppressor due to the frame-shifted ORF. | ||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | BARD1 | GO:0046826 | negative regulation of protein export from nucleus | 15265711 |
| Hgene | BARD1 | GO:0085020 | protein K6-linked ubiquitination | 12890688|20351172 |
| Fusion gene breakpoints across BARD1 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
 |
| Fusion gene breakpoints across C6orf222 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
 |
| Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChimerDB4 | ESCA | TCGA-L5-A8NT-01A | BARD1 | chr2 | 215645284 | - | C6orf222 | chr6 | 36291967 | - |
| ChimerDB4 | ESCA | TCGA-L5-A8NT | BARD1 | chr2 | 215645283 | - | C6orf222 | chr6 | 36291967 | - |
Top |
Fusion Gene ORF analysis for BARD1-C6orf222 |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| Frame-shift | ENST00000260947 | ENST00000437635 | BARD1 | chr2 | 215645284 | - | C6orf222 | chr6 | 36291967 | - |
| Frame-shift | ENST00000260947 | ENST00000437635 | BARD1 | chr2 | 215645283 | - | C6orf222 | chr6 | 36291967 | - |
| In-frame | ENST00000449967 | ENST00000437635 | BARD1 | chr2 | 215645284 | - | C6orf222 | chr6 | 36291967 | - |
| In-frame | ENST00000449967 | ENST00000437635 | BARD1 | chr2 | 215645283 | - | C6orf222 | chr6 | 36291967 | - |
| intron-3CDS | ENST00000432456 | ENST00000437635 | BARD1 | chr2 | 215645284 | - | C6orf222 | chr6 | 36291967 | - |
| intron-3CDS | ENST00000432456 | ENST00000437635 | BARD1 | chr2 | 215645283 | - | C6orf222 | chr6 | 36291967 | - |
| intron-3CDS | ENST00000471787 | ENST00000437635 | BARD1 | chr2 | 215645284 | - | C6orf222 | chr6 | 36291967 | - |
| intron-3CDS | ENST00000471787 | ENST00000437635 | BARD1 | chr2 | 215645283 | - | C6orf222 | chr6 | 36291967 | - |
| ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
| ENST00000449967 | BARD1 | chr2 | 215645283 | - | ENST00000437635 | C6orf222 | chr6 | 36291967 | - | 3659 | 1269 | 321 | 1364 | 347 |
| ENST00000449967 | BARD1 | chr2 | 215645284 | - | ENST00000437635 | C6orf222 | chr6 | 36291967 | - | 3659 | 1269 | 321 | 1364 | 347 |
| DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
| ENST00000449967 | ENST00000437635 | BARD1 | chr2 | 215645283 | - | C6orf222 | chr6 | 36291967 | - | 0.003538866 | 0.9964611 |
| ENST00000449967 | ENST00000437635 | BARD1 | chr2 | 215645284 | - | C6orf222 | chr6 | 36291967 | - | 0.003538866 | 0.9964611 |
Top |
Fusion Genomic Features for BARD1-C6orf222 |
| FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
| Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page. |
 |
Top |
Fusion Protein Features for BARD1-C6orf222 |
| Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr2:215645283/chr6:36291967) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| BARD1 | . |
| FUNCTION: E3 ubiquitin-protein ligase. The BRCA1-BARD1 heterodimer specifically mediates the formation of 'Lys-6'-linked polyubiquitin chains and coordinates a diverse range of cellular pathways such as DNA damage repair, ubiquitination and transcriptional regulation to maintain genomic stability. Plays a central role in the control of the cell cycle in response to DNA damage. Acts by mediating ubiquitin E3 ligase activity that is required for its tumor suppressor function. Also forms a heterodimer with CSTF1/CSTF-50 to modulate mRNA processing and RNAP II stability by inhibiting pre-mRNA 3' cleavage. {ECO:0000269|PubMed:12890688, ECO:0000269|PubMed:14976165, ECO:0000269|PubMed:20351172}. | FUNCTION: Transcriptional activator which is required for calcium-dependent dendritic growth and branching in cortical neurons. Recruits CREB-binding protein (CREBBP) to nuclear bodies. Component of the CREST-BRG1 complex, a multiprotein complex that regulates promoter activation by orchestrating a calcium-dependent release of a repressor complex and a recruitment of an activator complex. In resting neurons, transcription of the c-FOS promoter is inhibited by BRG1-dependent recruitment of a phospho-RB1-HDAC1 repressor complex. Upon calcium influx, RB1 is dephosphorylated by calcineurin, which leads to release of the repressor complex. At the same time, there is increased recruitment of CREBBP to the promoter by a CREST-dependent mechanism, which leads to transcriptional activation. The CREST-BRG1 complex also binds to the NR2B promoter, and activity-dependent induction of NR2B expression involves a release of HDAC1 and recruitment of CREBBP (By similarity). {ECO:0000250}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| Hgene | BARD1 | chr2:215645283 | chr6:36291967 | ENST00000260947 | - | 4 | 11 | 400_403 | 438 | 778.0 | Compositional bias | Note=Poly-Ser |
| Hgene | BARD1 | chr2:215645284 | chr6:36291967 | ENST00000260947 | - | 4 | 11 | 400_403 | 438 | 778.0 | Compositional bias | Note=Poly-Ser |
| Hgene | BARD1 | chr2:215645283 | chr6:36291967 | ENST00000260947 | - | 4 | 11 | 50_87 | 438 | 778.0 | Zinc finger | RING-type |
| Hgene | BARD1 | chr2:215645284 | chr6:36291967 | ENST00000260947 | - | 4 | 11 | 50_87 | 438 | 778.0 | Zinc finger | RING-type |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| Hgene | BARD1 | chr2:215645283 | chr6:36291967 | ENST00000260947 | - | 4 | 11 | 542_545 | 438 | 778.0 | Compositional bias | Note=Poly-Leu |
| Hgene | BARD1 | chr2:215645284 | chr6:36291967 | ENST00000260947 | - | 4 | 11 | 542_545 | 438 | 778.0 | Compositional bias | Note=Poly-Leu |
| Hgene | BARD1 | chr2:215645283 | chr6:36291967 | ENST00000260947 | - | 4 | 11 | 560_653 | 438 | 778.0 | Domain | BRCT 1 |
| Hgene | BARD1 | chr2:215645283 | chr6:36291967 | ENST00000260947 | - | 4 | 11 | 667_777 | 438 | 778.0 | Domain | BRCT 2 |
| Hgene | BARD1 | chr2:215645284 | chr6:36291967 | ENST00000260947 | - | 4 | 11 | 560_653 | 438 | 778.0 | Domain | BRCT 1 |
| Hgene | BARD1 | chr2:215645284 | chr6:36291967 | ENST00000260947 | - | 4 | 11 | 667_777 | 438 | 778.0 | Domain | BRCT 2 |
| Hgene | BARD1 | chr2:215645283 | chr6:36291967 | ENST00000260947 | - | 4 | 11 | 554_558 | 438 | 778.0 | Region | Note=Flexible linker |
| Hgene | BARD1 | chr2:215645284 | chr6:36291967 | ENST00000260947 | - | 4 | 11 | 554_558 | 438 | 778.0 | Region | Note=Flexible linker |
| Hgene | BARD1 | chr2:215645283 | chr6:36291967 | ENST00000260947 | - | 4 | 11 | 427_459 | 438 | 778.0 | Repeat | Note=ANK 1 |
| Hgene | BARD1 | chr2:215645283 | chr6:36291967 | ENST00000260947 | - | 4 | 11 | 460_492 | 438 | 778.0 | Repeat | Note=ANK 2 |
| Hgene | BARD1 | chr2:215645283 | chr6:36291967 | ENST00000260947 | - | 4 | 11 | 493_525 | 438 | 778.0 | Repeat | Note=ANK 3 |
| Hgene | BARD1 | chr2:215645283 | chr6:36291967 | ENST00000260947 | - | 4 | 11 | 526_546 | 438 | 778.0 | Repeat | Note=ANK 4%3B degenerate |
| Hgene | BARD1 | chr2:215645284 | chr6:36291967 | ENST00000260947 | - | 4 | 11 | 427_459 | 438 | 778.0 | Repeat | Note=ANK 1 |
| Hgene | BARD1 | chr2:215645284 | chr6:36291967 | ENST00000260947 | - | 4 | 11 | 460_492 | 438 | 778.0 | Repeat | Note=ANK 2 |
| Hgene | BARD1 | chr2:215645284 | chr6:36291967 | ENST00000260947 | - | 4 | 11 | 493_525 | 438 | 778.0 | Repeat | Note=ANK 3 |
| Hgene | BARD1 | chr2:215645284 | chr6:36291967 | ENST00000260947 | - | 4 | 11 | 526_546 | 438 | 778.0 | Repeat | Note=ANK 4%3B degenerate |
Top |
Fusion Gene Sequence for BARD1-C6orf222 |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
| >8977_8977_1_BARD1-C6orf222_BARD1_chr2_215645283_ENST00000449967_C6orf222_chr6_36291967_ENST00000437635_length(transcript)=3659nt_BP=1269nt AGAGCTTGGCCGGTTTCGAGTCGCTGGCCTGCAGCTTCCCTGTGGTTTCCCGAGGCTTCCTTGCTTCCCGCTCTGCGAGGAGCCTTTCAT CCGAAGGCGGGACGATGCCGGATAATCGGCAGCCGAGGAACCGGCAGCCGAGGATCCGCTCCGGGAACGAGCCTCGTTCCGCGCCCGCCA TGGAACCGGATGGTCGCGGTGCCTGGGCCCACAGTCGCGCCGCGCTCGACCGCCTGGAGAAGCTGCTGCGCTGCTCGCGTTGTACTAACA TTCTGAGAGAGCCTGTGTGTTTAGGAGGATGTGAGCACATCTTCTGTAGATTTGAAAGAAGATAAACCTAGGAAAAGTTTGTTTAATGAT GCAGGAAACAAGAAGAATTCAATTAAAATGTGGTTTAGCCCTCGAAGTAAGAAAGTCAGATATGTTGTGAGTAAAGCTTCAGTGCAAACC CAGCCTGCAATAAAAAAAGATGCAAGTGCTCAGCAAGACTCATATGAATTTGTTTCCCCAAGTCCTCCTGCAGATGTTTCTGAGAGGGCT AAAAAGGCTTCTGCAAGATCTGGAAAAAAGCAAAAAAAGAAAACTTTAGCTGAAATCAACCAAAAATGGAATTTAGAGGCAGAAAAAGAA GATGGTGAATTTGACTCCAAAGAGGAATCTAAGCAAAAGCTGGTATCCTTCTGTAGCCAACCATCTGTTATCTCCAGTCCTCAGATAAAT GGTGAAATAGACTTACTAGCAAGTGGCTCCTTGACAGAATCTGAATGTTTTGGAAGTTTAACTGAAGTCTCTTTACCATTGGCTGAGCAA ATAGAGTCTCCAGACACTAAGAGCAGGAATGAAGTAGTGACTCCTGAGAAGGTCTGCAAAAATTATCTTACATCTAAGAAATCTTTGCCA TTAGAAAATAATGGAAAACGTGGCCATCACAATAGACTTTCCAGTCCCATTTCTAAGAGATGTAGAACCAGCATTCTGAGCACCAGTGGA GATTTTGTTAAGCAAACGGTGCCCTCAGAAAATATACCATTGCCTGAATGTTCTTCACCACCTTCATGCAAACGTAAAGTTGGTGGTACA TCAGGGAGGAAAAACAGTAACATGTCCGATGAATTCATTAGTCTTTCACCAGGTACACCACCTTCTACATTAAGTAGTTCAAGTTACAGG CGAGTGATGTCTAGTCCCTCAGCAATGAAGCTGTTGCCCAATATGGCTGTGAAAAGAAATCATAGAGGAGAGACTTTGCTCCATATTGCT TCTATTAAGAAGAATTCATTCAGAAGATCATTTCCATGCTCCAAGATGCAGAAGAACAGCAAGGAGAGGAGCAACCTCAAGTCCAGCAGG AAGAGGTGGGTGTAGAAAACCCGGCCCCACACTGCAGAAGGAAATCTCAAGAAAAAAGGTCGAGCTTCAGGAGAGCGTTTTACCATAAGA AACACACCTCCAAGGAACCCAGAAGAGCGGGGGCAGCAGGGGCTGCCAGCCCAGAGGCCCGACGACCCAAGAGGCCCAGCTTTCTGCCCC TGTGTGTTGGTGGCCATCGGCCCTCCACCTCCAGCAGCCTTGATCCAGAAGATCTCGAGTGCCGGGAGCCCCTGCCCGCAGAAGGGGAGC CAGTTGTGATCTCAGAAGCACCCTCCCAGGCTAGAGGCCACACGCCAGAAGGGGCACCTCAGCTGAGTGGAGCATGTGAATCTAAGGAGA TCATCATCCAGAAGCTTGTGGCACTTCTCCAAGAAGTGGATGGCCAACTGGGGCAGCAGATCAGGCGCCACCCCAGCTTTAAGAGGTTTT TTTACGAGTTCTCGGACTCCTCCCTCAGCAAGCTGGTAGCCACCCTGCGCAGCCAGGTGGCTCACTCCTCTAAGCTGGACAGGAACCGCG CCAGGAGACTCTACCAGTTTGACGTTAGCTTAGCTAACAAATTTGCTGGCAGCAACAGCCATGCCATGTGCATCCTCATGGGCCTAAGAG ACCACTACAATTGCACCCAGTTCCCATACAGGGAGGACCAGCCGAACATCACAAGTCCTAAGGTTGAAAGTCCAGATTGAAAGCTGTGTC TTGCACTCAAATTCCCTTGAACTAGCCAAATGGTTCGCAGCTTTAGCCAGGAGACCCTGAAGATGCTCTGTGATGTCCCAATCCCTGCTT CACAAACGTGATGGAAGACAAGAGCAGACAATCATTCTGTGTCCATACCCTAGTATCTGAGAAGCACAGAGCATTCTTCCACAAGGCAAG ACACAGAGGCCATGTCTGGGGAAATCAGCACTGGACTGGGAATGAGGAAGACTGGGGCTCTACCTGCTGAACCTACCCCAGACTTGCTGC ATGACCCTCTACACATTCCCCCTCCTCTCCAGACTTTGGAGTCTAGGATCCCACCCAGAAGGCCTACTGATATTTTCTCAGATGTTCATG TTAACTGAGTCTAGTTTTTAAACTAAATTTTTATTTAATCTCTAAACAGAACATCCACATGCATCCAAACAGATATGCATCGAAGTGTAT CCCATCATTTCTTCAGTTGACCAGTAGTTCTTCATGCTCATATGGATTTGTAGATGCCTCCCAGGAACTCTGCAGGCCCAAGATGGAAAA ACCTAGAGACTGGGGACACTTGGTCTCTCAGAATCCTTCTAACCCTGTGTCCTGTCATTCTATGACTAGAGAAATGGAGCTGATACCTTG CACCTCTCCCATCTCATGGGATTGGCTAGGAGTCAGTGAGAAAATGGATGTGAAGAGTTCTGAAAATTACCTAGTGCCATGTCCATGTAG GCACTATAGCTTCTTTTGGGTAGTTTTCAGGAAGTGGAGGAGGGCTTCAATGGGCTGGACTGCCATGGATTGTTGCACAGGGGTGCACTG CTCAAGAGCACCATACTCCAGGAGGTACTATTCATGTCCTAGACATTGTGGATTTGTAGATTTATCATGACAGTTTTGCAGCTGGTAGCA GTAACATGTCTTGAGAAAAGGGCTATTTTTTGTATTTGCACAAAGGTGAAGTGTGGGGGTGCCAGAGGCTCTGCCTTCTGTATAGCTCAA CAGTTTCAATAGCTTGACTCAGGTGTGAAATTTGCCACATGTTCATATCTATGTGCAGGAAGGACAAGACTGTAGACAGACAGTCGGCTC CCTTGGACACTGCCCAGAACATGTGGTCATGGGGGAAAGGGTGTTAAACCTGGATGGCAAGTGAGATCTTGTGACCCTTGGGGACATGGT ATTGCCGTGTTGAACCTGCTGTCGCACCATGGGGTAGGACTGGGGAGGAGGAGCAGTCTAGAGCGGAGAGGCCCTGGGTGCTTATATGGG ACTGGCCTCCAACCTGAGGCACTGGCTTCATAAGCTCAACTCAGCCTATCCGGAAAGCCATTTAGTTTTTATTGCTGCTTCTGAGAAGTG GGGGAGAGGTGAGCTATTTGTGGATTTGTTTTAGGCAGTGTTCACAATCATAGCACCTAAATATGAAGGATCAGAATAAGTTATGAAATG AAGGTCAGGAACCTTTTGTACATAGTTTCTTATTTGGAATGATGTTCTTTAAGCCCTATGAGTATTTGGTATGTGCTCCTGATGCTGGCA >8977_8977_1_BARD1-C6orf222_BARD1_chr2_215645283_ENST00000449967_C6orf222_chr6_36291967_ENST00000437635_length(amino acids)=347AA_BP=316 MKEDKPRKSLFNDAGNKKNSIKMWFSPRSKKVRYVVSKASVQTQPAIKKDASAQQDSYEFVSPSPPADVSERAKKASARSGKKQKKKTLA EINQKWNLEAEKEDGEFDSKEESKQKLVSFCSQPSVISSPQINGEIDLLASGSLTESECFGSLTEVSLPLAEQIESPDTKSRNEVVTPEK VCKNYLTSKKSLPLENNGKRGHHNRLSSPISKRCRTSILSTSGDFVKQTVPSENIPLPECSSPPSCKRKVGGTSGRKNSNMSDEFISLSP -------------------------------------------------------------- >8977_8977_2_BARD1-C6orf222_BARD1_chr2_215645284_ENST00000449967_C6orf222_chr6_36291967_ENST00000437635_length(transcript)=3659nt_BP=1269nt AGAGCTTGGCCGGTTTCGAGTCGCTGGCCTGCAGCTTCCCTGTGGTTTCCCGAGGCTTCCTTGCTTCCCGCTCTGCGAGGAGCCTTTCAT CCGAAGGCGGGACGATGCCGGATAATCGGCAGCCGAGGAACCGGCAGCCGAGGATCCGCTCCGGGAACGAGCCTCGTTCCGCGCCCGCCA TGGAACCGGATGGTCGCGGTGCCTGGGCCCACAGTCGCGCCGCGCTCGACCGCCTGGAGAAGCTGCTGCGCTGCTCGCGTTGTACTAACA TTCTGAGAGAGCCTGTGTGTTTAGGAGGATGTGAGCACATCTTCTGTAGATTTGAAAGAAGATAAACCTAGGAAAAGTTTGTTTAATGAT GCAGGAAACAAGAAGAATTCAATTAAAATGTGGTTTAGCCCTCGAAGTAAGAAAGTCAGATATGTTGTGAGTAAAGCTTCAGTGCAAACC CAGCCTGCAATAAAAAAAGATGCAAGTGCTCAGCAAGACTCATATGAATTTGTTTCCCCAAGTCCTCCTGCAGATGTTTCTGAGAGGGCT AAAAAGGCTTCTGCAAGATCTGGAAAAAAGCAAAAAAAGAAAACTTTAGCTGAAATCAACCAAAAATGGAATTTAGAGGCAGAAAAAGAA GATGGTGAATTTGACTCCAAAGAGGAATCTAAGCAAAAGCTGGTATCCTTCTGTAGCCAACCATCTGTTATCTCCAGTCCTCAGATAAAT GGTGAAATAGACTTACTAGCAAGTGGCTCCTTGACAGAATCTGAATGTTTTGGAAGTTTAACTGAAGTCTCTTTACCATTGGCTGAGCAA ATAGAGTCTCCAGACACTAAGAGCAGGAATGAAGTAGTGACTCCTGAGAAGGTCTGCAAAAATTATCTTACATCTAAGAAATCTTTGCCA TTAGAAAATAATGGAAAACGTGGCCATCACAATAGACTTTCCAGTCCCATTTCTAAGAGATGTAGAACCAGCATTCTGAGCACCAGTGGA GATTTTGTTAAGCAAACGGTGCCCTCAGAAAATATACCATTGCCTGAATGTTCTTCACCACCTTCATGCAAACGTAAAGTTGGTGGTACA TCAGGGAGGAAAAACAGTAACATGTCCGATGAATTCATTAGTCTTTCACCAGGTACACCACCTTCTACATTAAGTAGTTCAAGTTACAGG CGAGTGATGTCTAGTCCCTCAGCAATGAAGCTGTTGCCCAATATGGCTGTGAAAAGAAATCATAGAGGAGAGACTTTGCTCCATATTGCT TCTATTAAGAAGAATTCATTCAGAAGATCATTTCCATGCTCCAAGATGCAGAAGAACAGCAAGGAGAGGAGCAACCTCAAGTCCAGCAGG AAGAGGTGGGTGTAGAAAACCCGGCCCCACACTGCAGAAGGAAATCTCAAGAAAAAAGGTCGAGCTTCAGGAGAGCGTTTTACCATAAGA AACACACCTCCAAGGAACCCAGAAGAGCGGGGGCAGCAGGGGCTGCCAGCCCAGAGGCCCGACGACCCAAGAGGCCCAGCTTTCTGCCCC TGTGTGTTGGTGGCCATCGGCCCTCCACCTCCAGCAGCCTTGATCCAGAAGATCTCGAGTGCCGGGAGCCCCTGCCCGCAGAAGGGGAGC CAGTTGTGATCTCAGAAGCACCCTCCCAGGCTAGAGGCCACACGCCAGAAGGGGCACCTCAGCTGAGTGGAGCATGTGAATCTAAGGAGA TCATCATCCAGAAGCTTGTGGCACTTCTCCAAGAAGTGGATGGCCAACTGGGGCAGCAGATCAGGCGCCACCCCAGCTTTAAGAGGTTTT TTTACGAGTTCTCGGACTCCTCCCTCAGCAAGCTGGTAGCCACCCTGCGCAGCCAGGTGGCTCACTCCTCTAAGCTGGACAGGAACCGCG CCAGGAGACTCTACCAGTTTGACGTTAGCTTAGCTAACAAATTTGCTGGCAGCAACAGCCATGCCATGTGCATCCTCATGGGCCTAAGAG ACCACTACAATTGCACCCAGTTCCCATACAGGGAGGACCAGCCGAACATCACAAGTCCTAAGGTTGAAAGTCCAGATTGAAAGCTGTGTC TTGCACTCAAATTCCCTTGAACTAGCCAAATGGTTCGCAGCTTTAGCCAGGAGACCCTGAAGATGCTCTGTGATGTCCCAATCCCTGCTT CACAAACGTGATGGAAGACAAGAGCAGACAATCATTCTGTGTCCATACCCTAGTATCTGAGAAGCACAGAGCATTCTTCCACAAGGCAAG ACACAGAGGCCATGTCTGGGGAAATCAGCACTGGACTGGGAATGAGGAAGACTGGGGCTCTACCTGCTGAACCTACCCCAGACTTGCTGC ATGACCCTCTACACATTCCCCCTCCTCTCCAGACTTTGGAGTCTAGGATCCCACCCAGAAGGCCTACTGATATTTTCTCAGATGTTCATG TTAACTGAGTCTAGTTTTTAAACTAAATTTTTATTTAATCTCTAAACAGAACATCCACATGCATCCAAACAGATATGCATCGAAGTGTAT CCCATCATTTCTTCAGTTGACCAGTAGTTCTTCATGCTCATATGGATTTGTAGATGCCTCCCAGGAACTCTGCAGGCCCAAGATGGAAAA ACCTAGAGACTGGGGACACTTGGTCTCTCAGAATCCTTCTAACCCTGTGTCCTGTCATTCTATGACTAGAGAAATGGAGCTGATACCTTG CACCTCTCCCATCTCATGGGATTGGCTAGGAGTCAGTGAGAAAATGGATGTGAAGAGTTCTGAAAATTACCTAGTGCCATGTCCATGTAG GCACTATAGCTTCTTTTGGGTAGTTTTCAGGAAGTGGAGGAGGGCTTCAATGGGCTGGACTGCCATGGATTGTTGCACAGGGGTGCACTG CTCAAGAGCACCATACTCCAGGAGGTACTATTCATGTCCTAGACATTGTGGATTTGTAGATTTATCATGACAGTTTTGCAGCTGGTAGCA GTAACATGTCTTGAGAAAAGGGCTATTTTTTGTATTTGCACAAAGGTGAAGTGTGGGGGTGCCAGAGGCTCTGCCTTCTGTATAGCTCAA CAGTTTCAATAGCTTGACTCAGGTGTGAAATTTGCCACATGTTCATATCTATGTGCAGGAAGGACAAGACTGTAGACAGACAGTCGGCTC CCTTGGACACTGCCCAGAACATGTGGTCATGGGGGAAAGGGTGTTAAACCTGGATGGCAAGTGAGATCTTGTGACCCTTGGGGACATGGT ATTGCCGTGTTGAACCTGCTGTCGCACCATGGGGTAGGACTGGGGAGGAGGAGCAGTCTAGAGCGGAGAGGCCCTGGGTGCTTATATGGG ACTGGCCTCCAACCTGAGGCACTGGCTTCATAAGCTCAACTCAGCCTATCCGGAAAGCCATTTAGTTTTTATTGCTGCTTCTGAGAAGTG GGGGAGAGGTGAGCTATTTGTGGATTTGTTTTAGGCAGTGTTCACAATCATAGCACCTAAATATGAAGGATCAGAATAAGTTATGAAATG AAGGTCAGGAACCTTTTGTACATAGTTTCTTATTTGGAATGATGTTCTTTAAGCCCTATGAGTATTTGGTATGTGCTCCTGATGCTGGCA >8977_8977_2_BARD1-C6orf222_BARD1_chr2_215645284_ENST00000449967_C6orf222_chr6_36291967_ENST00000437635_length(amino acids)=347AA_BP=316 MKEDKPRKSLFNDAGNKKNSIKMWFSPRSKKVRYVVSKASVQTQPAIKKDASAQQDSYEFVSPSPPADVSERAKKASARSGKKQKKKTLA EINQKWNLEAEKEDGEFDSKEESKQKLVSFCSQPSVISSPQINGEIDLLASGSLTESECFGSLTEVSLPLAEQIESPDTKSRNEVVTPEK VCKNYLTSKKSLPLENNGKRGHHNRLSSPISKRCRTSILSTSGDFVKQTVPSENIPLPECSSPPSCKRKVGGTSGRKNSNMSDEFISLSP -------------------------------------------------------------- |
Top |
Fusion Gene PPI Analysis for BARD1-C6orf222 |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| Hgene | BARD1 | chr2:215645283 | chr6:36291967 | ENST00000260947 | - | 4 | 11 | 26_119 | 438.0 | 778.0 | BRCA1 |
| Hgene | BARD1 | chr2:215645284 | chr6:36291967 | ENST00000260947 | - | 4 | 11 | 26_119 | 438.0 | 778.0 | BRCA1 |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for BARD1-C6orf222 |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
Related Diseases for BARD1-C6orf222 |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Hgene | BARD1 | C0346153 | Breast Cancer, Familial | 11 | CLINGEN |
| Hgene | BARD1 | C0009405 | Hereditary Nonpolyposis Colorectal Neoplasms | 4 | CLINGEN |
| Hgene | BARD1 | C1112155 | Hereditary non-polyposis colorectal cancer syndrome | 4 | CLINGEN |
| Hgene | BARD1 | C1333990 | Hereditary Nonpolyposis Colorectal Cancer | 4 | CLINGEN |
| Hgene | BARD1 | C1333991 | Hereditary Non-Polyposis Colon Cancer Type 2 | 4 | CLINGEN |
| Hgene | BARD1 | C2936783 | Colorectal cancer, hereditary nonpolyposis, type 1 | 4 | CLINGEN |
| Hgene | BARD1 | C0027819 | Neuroblastoma | 2 | CTD_human |
| Hgene | BARD1 | C0677776 | Hereditary Breast and Ovarian Cancer Syndrome | 1 | ORPHANET |
Copyright 2021-Present -The University of Texas Health Science Center at Houston (UTHealth)
Web File Viewing | Emergency Information |Campus Carry|Site Policies